Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.

Korpanty G, Smyth E, Sullivan LA, Brekken RA, Carney DN.

Exp Biol Med (Maywood). 2010 Jan;235(1):3-9. doi: 10.1258/ebm.2009.009191. Review.

PMID:
20404013
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.

Horn L, Sandler AB.

Clin Lung Cancer. 2009 Mar;10 Suppl 1:S7-16. doi: 10.3816/CLC.2009.s.002. Review.

PMID:
19362948
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Antiangiogenic drugs in non-small cell lung cancer treatment.

Cascone T, Troiani T, Morelli MP, Gridelli C, Ciardiello F.

Curr Opin Oncol. 2006 Mar;18(2):151-5. Review.

PMID:
16462184
[PubMed - indexed for MEDLINE]
4.

Drug insight: VEGF as a therapeutic target for breast cancer.

Schneider BP, Sledge GW Jr.

Nat Clin Pract Oncol. 2007 Mar;4(3):181-9. Review.

PMID:
17327858
[PubMed - indexed for MEDLINE]
5.

Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer.

Yano S, Matsumori Y, Ikuta K, Ogino H, Doljinsuren T, Sone S.

Int J Clin Oncol. 2006 Apr;11(2):73-81. Review.

PMID:
16622742
[PubMed - indexed for MEDLINE]
6.

Circulating endothelial and endothelial progenitor cells in non-small-cell lung cancer.

Fleitas T, Martínez-Sales V, Gómez-Codina J, Martín M, Reynés G.

Clin Transl Oncol. 2010 Aug;12(8):521-5. doi: 10.1007/s12094-010-0549-x. Review.

PMID:
20709649
[PubMed - indexed for MEDLINE]
7.

[Targeted therapies and radiation therapy in non-small cell lung cancer].

Rivera S, Quéro L, Wong Hee Kam S, Maylin C, Deutsch E, Hennequin C.

Cancer Radiother. 2011 Oct;15(6-7):527-35. doi: 10.1016/j.canrad.2011.07.234. Epub 2011 Aug 31. Review. French.

PMID:
21885318
[PubMed - indexed for MEDLINE]
8.

Antiangiogenic therapy in nonsmall cell lung cancer.

Gutierrez M, Giaccone G.

Curr Opin Oncol. 2008 Mar;20(2):176-82. doi: 10.1097/CCO.0b013e3282f4e55e. Review.

PMID:
18300767
[PubMed - indexed for MEDLINE]
9.

Targeting tumor neovasculature in non-small-cell lung cancer.

Pallis AG, Syrigos KN.

Crit Rev Oncol Hematol. 2013 May;86(2):130-42. doi: 10.1016/j.critrevonc.2012.10.003. Epub 2012 Nov 15. Review.

PMID:
23159217
[PubMed - indexed for MEDLINE]
10.

Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.

Auberger J, Loeffler-Ragg J, Wurzer W, Hilbe W.

Curr Cancer Drug Targets. 2006 Jun;6(4):271-94. Review.

PMID:
16848720
[PubMed - indexed for MEDLINE]
11.

[Are antiangiogenic antibodies universal for solid tumor?].

Ray-Coquard I, Bachelot T, Saba C, Confavreux C, Brantus JF, Rustam F, Ghesquière H, Sebban C, Biron P, Guastalla JP, Blay JY.

Bull Cancer. 2007 Jul;94 Spec No:S191-6. Review. French.

PMID:
17846004
[PubMed - indexed for MEDLINE]
12.

Angiogenesis in the treatment of non-small cell lung cancer.

Horn L, Sandler AB.

Proc Am Thorac Soc. 2009 Apr 15;6(2):206-17. doi: 10.1513/pats.200807-066LC. Review.

PMID:
19349490
[PubMed - indexed for MEDLINE]
13.

Anti-angiogenic and anti-HER therapy.

Gasparini G, Sarmiento R, Longo R.

Biomed Pharmacother. 2006 Jul;60(6):263-5. Epub 2006 Jun 23. Review.

PMID:
16815667
[PubMed - indexed for MEDLINE]
14.

Targeting tumorangiogenesis in lung cancer by suppression of VEGF and its receptor - results from clinical trials and novel experimental approaches.

Kuhn H, Hammerschmidt S, Wirtz H.

Curr Med Chem. 2007;14(30):3157-65. Review.

PMID:
18220749
[PubMed - indexed for MEDLINE]
15.

Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474.

Morgensztern D, Govindan R.

Expert Rev Anticancer Ther. 2006 Apr;6(4):545-51. Review.

PMID:
16613542
[PubMed - indexed for MEDLINE]
16.

Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer.

Blackhall FH, Shepherd FA.

Hematol Oncol Clin North Am. 2004 Oct;18(5):1121-41, ix. Review.

PMID:
15474338
[PubMed - indexed for MEDLINE]
17.

Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.

Grothey A, Ellis LM.

Cancer J. 2008 May-Jun;14(3):170-7. doi: 10.1097/PPO.0b013e318178d9de. Review.

PMID:
18536556
[PubMed - indexed for MEDLINE]
18.

The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.

Langer CJ, Natale RB.

Semin Oncol. 2005 Dec;32(6 Suppl 10):S23-9. Review.

PMID:
16459176
[PubMed - indexed for MEDLINE]
19.

[Angiogenesis: a new therapeutic target of thoracic and laryngopharyngeal carcinoma].

Taillade L, Alexandre I, Billemont B, Meric JB, Sultan-Amar V, Rixe O.

Bull Cancer. 2009;96 Suppl 1:S45-55. doi: 10.1684/bdc.2008.0775. Review. French.

PMID:
19433373
[PubMed - indexed for MEDLINE]
20.

Angiogenesis inhibitors in the treatment of lung cancer.

Sun S, Schiller JH.

Crit Rev Oncol Hematol. 2007 May;62(2):93-104. Epub 2007 Feb 15. Review.

PMID:
17306557
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk